Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 1
1986 1
1997 4
2002 2
2003 2
2004 2
2005 2
2006 1
2008 3
2009 2
2010 4
2011 2
2012 7
2013 10
2014 6
2015 6
2016 10
2017 12
2018 7
2019 17
2020 11
2021 22
2022 26
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %
The following terms were not found in PubMed: 22Digestive, 2Fepidemiology, 5BMAJR
Page 1
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Motzer R, et al. Lancet Oncol. 2022 Jun;23(6):768-780. doi: 10.1016/S1470-2045(22)00212-1. Epub 2022 Apr 27. Lancet Oncol. 2022. PMID: 35489363 Free PMC article. Clinical Trial.
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and the EQ-5D-3 Level (EQ-5D-3L) preference …
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Resea …
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. ...PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol- …
Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positi …
Evaluation of content on EQ-5D as compared to disease-specific utility measures.
Lin FJ, Longworth L, Pickard AS. Lin FJ, et al. Qual Life Res. 2013 May;22(4):853-74. doi: 10.1007/s11136-012-0207-6. Epub 2012 Jun 23. Qual Life Res. 2013. PMID: 22729670 Review.
PURPOSE: The goal of this study was to appraise the extent of unique content on disease-specific preference-based measures (DSPMs) when contrasted with the EQ-5D using published studies and to inform whether EQ-5D could be inadequate as a utility measure in i …
PURPOSE: The goal of this study was to appraise the extent of unique content on disease-specific preference-based measures (DSPMs) wh …
A systematic review of health state utility values in Thai cancer patients.
Kangwanrattanakul K. Kangwanrattanakul K. Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1171-1186. doi: 10.1080/14737167.2022.2123796. Epub 2022 Sep 26. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 36084926
The EQ-5D 3 Level Version was commonly used to identify the HSUVs of Thai patients with cancer. Meanwhile, the use of the EQ-5D 5 Level Version was supported by psychometric testing. However, mapping techniques between disease-specific and health preference-b …
The EQ-5D 3 Level Version was commonly used to identify the HSUVs of Thai patients with cancer. Meanwhile, the use of the EQ-5D
Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.
Allanore Y, Constans J, Godard D, de Pouvourville G, Bouee S, Jeanbat V, Teissier C, Le Lay K, Chollet J, Hachulla E. Allanore Y, et al. J Scleroderma Relat Disord. 2022 Feb;7(1):49-56. doi: 10.1177/23971983211013979. Epub 2021 Jun 21. J Scleroderma Relat Disord. 2022. PMID: 35386942 Free PMC article.
RESULTS: In all, 89 patients were included. 26.4% were males, mean age was 58.2 14.5 years. Mean EQ-5D-5L score = 0.79 0.22 (median = 0.85). Mean EQ-5D-5L visual analog scale score = 60.8 20.4 (median = 61.5). ...No significant correlation between forced vita …
RESULTS: In all, 89 patients were included. 26.4% were males, mean age was 58.2 14.5 years. Mean EQ-5D-5L score = 0.79 0.22 (m …
Three 'D's: Design approach, dimensional printing, and drug delivery systems as promising tools in healthcare applications.
Rahman M, Almalki WH, Alghamdi S, Alharbi KS, Khalilullah H, Habban Akhter M, Keshari AK, Sharma N, Singh T, Soni K, Hafeez A, Beg S. Rahman M, et al. Drug Discov Today. 2021 Nov;26(11):2726-2733. doi: 10.1016/j.drudis.2021.06.016. Epub 2021 Jul 6. Drug Discov Today. 2021. PMID: 34242795 Review.
The development of pharmaceutical drug products is required for the treatment of disease, which has resulted in an increasing number of approvals by regulatory agencies across the globe. ...Printing technology has been emerged in various dimensions, such as 3D, 4D, and …
The development of pharmaceutical drug products is required for the treatment of disease, which has resulted in an increasing number …
Humanistic and cost burden of systemic sclerosis: A review of the literature.
Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Fischer A, et al. Autoimmun Rev. 2017 Nov;16(11):1147-1154. doi: 10.1016/j.autrev.2017.09.010. Epub 2017 Sep 9. Autoimmun Rev. 2017. PMID: 28899803 Free article. Review.
Current treatments for SSc manage a range of symptoms but not the cause of the disease. Our review describes the humanistic and cost burden of SSc. ...In addition, SSc places a considerable economic burden on health care systems and society as a whole....
Current treatments for SSc manage a range of symptoms but not the cause of the disease. Our review describes the humanistic and cost …
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Saad F, et al. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2. Lancet Oncol. 2022. PMID: 36063830 Clinical Trial.
Randomisation was done without stratification and by use of an interactive voice or web response system. A randomised treatment kit ID number was assigned sequentially to each patient as they became eligible. ...Time to deterioration in pain was similar in both groups (BPI …
Randomisation was done without stratification and by use of an interactive voice or web response system. A randomised treatment kit I …
A pilot prospective prevalence study of chronic rhinosinusitis associated with inflammatory bowel disease.
Dhillon I, Ham J, Maul X, Rosenfeld G, Thamboo A. Dhillon I, et al. World J Otorhinolaryngol Head Neck Surg. 2022 Mar 14;8(4):339-344. doi: 10.1002/wjo2.17. eCollection 2022 Dec. World J Otorhinolaryngol Head Neck Surg. 2022. PMID: 36474669 Free PMC article.
Ninety-two CRS patients were screened for IBD symptoms from October 2018 to January 2020. Patient-reported disease symptoms and overall quality of life were evaluated using the Sino-Nasal Outcome Test 22 (SNOT-22), Short Inflammatory Bowel Disease Ques …
Ninety-two CRS patients were screened for IBD symptoms from October 2018 to January 2020. Patient-reported disease symptoms and overa …
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
Xu RH, Dong D, Luo N, Wong EL, Wu Y, Yu S, Yang R, Liu J, Yuan H, Zhang S. Xu RH, et al. Eur J Health Econ. 2021 Jun;22(4):547-557. doi: 10.1007/s10198-021-01273-5. Epub 2021 Mar 24. Eur J Health Econ. 2021. PMID: 33761029
RESULTS: Both the EQ-5D-5L and SF-6D indices showed acceptable ceiling and floor effects. ...The F statistics in the known-groups comparisons suggested that the EQ-5D-5L was slightly more discriminative than the SF-6D. ICC (0.41) and Bland-Altman plot confirmed that …
RESULTS: Both the EQ-5D-5L and SF-6D indices showed acceptable ceiling and floor effects. ...The F statistics in the known-groups com …
162 results